Search Results - "Sacré, Anne"

Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants by Freire, Maria Valeria, Martin, Marie, Thissen, Romain, Van Marcke, Cédric, Segers, Karin, Sépulchre, Edith, Leroi, Natacha, Lété, Céline, Fasquelle, Corinne, Radermacher, Jean, Gokburun, Yeter, Collignon, Joelle, Sacré, Anne, Josse, Claire, Palmeira, Leonor, Bours, Vincent

“…The link between and homologous recombination deficiency (HRD) in cancer has gained importance with the emergence of new targeted cancer treatments, while the…”
Get full text

Regorafenib induced severe toxic hepatitis: characterization and discussion by Sacré, Anne, Lanthier, Nicolas, Dano, Hélène, Aydin, Selda, Leggenhager, Daniela, Weber, Achim, Dekairelle, Anne-France, De Cuyper, Astrid, Gala, Jean-Luc, Humblet, Yves, Sempoux, Christine, Van den Eynde, Marc

“…Background Regorafenib is the first small‐molecule multikinase inhibitor which showed survival benefits in pretreated metastatic colorectal cancer (mCRC)…”
Get full text

Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor by Sacré, Anne, Barthélémy, Philippe, Korenbaum, Clement, Burgy, Mickael, Wolter, Pascal, Dumez, Herlinde, Lerut, Evelyne, Loyson, Tine, Joniau, Steven, Oyen, Raymond, Debruyne, Philip R, Schöffski, Patrick, Beuselinck, Benoit

“…About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients receive a second-line targeted therapy after failure of anti-vascular endothelial…”
Get more information

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial by Grimm, Marc-Oliver, Esteban, Emilio, Barthélémy, Philippe, Schmidinger, Manuela, Busch, Jonas, Valderrama, Begoña P, Charnley, Natalie, Schmitz, Marc, Schumacher, Ulrike, Leucht, Katharina, Foller, Susan, Baretton, Gustavo, Duran, Ignacio, de Velasco, Guillermo, Priou, Frank, Maroto, Pablo, Albiges, Laurence

“…Nivolumab plus ipilimumab is approved as first-line regimen for intermediate-risk or poor-risk metastatic renal cell carcinoma, and nivolumab monotherapy as…”
Get full text

Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase by Sacré, Anne, Jouret, François, Manicourt, Daniel, Devuyst, Olivier

Get full text

Topiramate induces type 3 renal tubular acidosis by inhibiting renal carbonic anhydrase by Sacré, Anne, Jouret, François, Manicourt, Daniel, Devuyst, Olivier

Get full text